Stockreport

ImmunityBio immunotherapy shows positive overall survival in lung cancer trial [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF trial evaluating its immunotherapy drug, Anktiva, in non-small cell lung cancer (NSCLC). The QUILT 3.055 trial included 2nd- and 3rd-line NSCLC patients whose disease [Read more]